Price Wealth’s Alexion Pharmaceuticals ALXN Stock Holding History

Price Wealth’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$15K	Buy	130 +113	+665%	+$12.2K	﹤0.01%	230
2020 Q2	$2K	Buy	+17	New	+$1.8K	﹤0.01%	326
2019 Q4	–	Sell	-16	Closed	-$2K	–	488
2019 Q3	$2K	Hold	16	–	–	﹤0.01%	264
2019 Q2	$2K	Buy	+16	New	+$2.06K	﹤0.01%	261
2018 Q3	–	Sell	-18	Closed	-$2K	–	461
2018 Q2	$2K	Buy	+18	New	+$2.1K	﹤0.01%	475

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Price Wealth's ALXN Position: Q3 2020 in Review

Price Wealth increased its Alexion Pharmaceuticals (ALXN) stake by 665% in Q3 2020, buying an estimated $12.2K and bringing the position to 130 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #230.

Price Wealth first reported a position in ALXN in Q2 2018 and has held it in 5 quarters since. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Price Wealth held 130 shares of Alexion Pharmaceuticals worth $15K as of Q3 2020.
Price Wealth bought 113 Alexion Pharmaceuticals shares in Q3 2020, an estimated $12.2K.
Alexion Pharmaceuticals made up ﹤0.01% of Price Wealth's portfolio in Q3 2020, its #230 holding.
Price Wealth first reported a position in Alexion Pharmaceuticals in Q2 2018 and has held it in 5 quarters since.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Price Wealth's 13F filing for Q3 2020, filed 22 Oct 2020.